TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising pre-clinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuthill, Mark H, Montinaro, Antonella, Zinngrebe, Julia, Prieske, Katharina, Draber, Peter, Prieske, Stefan, Newsom-Davis, Tom, von Karstedt, Silvia, Graves, Jonathan, Walczak, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240732/
https://www.ncbi.nlm.nih.gov/pubmed/24909167
http://dx.doi.org/10.1038/onc.2014.156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240732/
https://www.ncbi.nlm.nih.gov/pubmed/24909167
http://dx.doi.org/10.1038/onc.2014.156

Ejemplares similares